Regulus Therapeutics focuses on developing therapeutics for patients with orphan kidney diseases, particularly targeting the underlying biology of these conditions with microRNA-based therapeutics.

Regulus Therapeutics

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

COM:REGULUSRX

Regulus Therapeutics

Last Close

1.41

12/11 20:39

Market Cap

115.22M

Beta: -

Volume Today

742.99K

Avg: -

Analysis Not Available